MPI and Oncology Venture enhances the collaboration by entering another agreement on DRP's

2016-07-05

Hoersholm; July 5th, 2016 - Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI has sold a DRP to Oncology Venture for a selected compound for anti-cancer treatment.

By adding to Oncology Ventures portfolio of DRP's supporting their novel way of developing cancer treatment, MPI is increasing the likelihood of achieving proof of concept of the DRP(TM) technology. Oncology Venture is finding anti cancer drugs that have achieved encouraging levels of complete and partial responses but not with a high enough response rate to secure approval. The drugs will, if they continue to fulfill OV's requirements and are successfully inlicensed, be developed with MPI's DRP(TM) to enrich the patient population and increase the response rate.

"It is encouraging that MPI can develop strong Drug Response Predictors for Oncology Ventures anti cancer drug development program. The aim is to have anti-cancer drugs approved - giving cancer patients a new Personalized Treatment option" says adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO at MPI. "The DRP(TM) can make a key difference and bring new and more effective treatments on the market." adds Peter Buhl Jensen.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messengerRNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.                              Ulla Hald Buhl, IR & Communication
E-mail: pbj@medical-prognosis.com                                                           E-mail: uhb@medical-prognosis.com
Telephone: +45 21 60 89 22                                                                                        Telephone +45 21 70 10 49

Certified Advisor: Ronny Farnebäck, Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden